Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above Two Hundred Day Moving Average of $3.14

Arbutus Biopharma Co. (NASDAQ:ABUS) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.14 and traded as high as $3.90. Arbutus Biopharma shares last traded at $3.87, with a volume of 2,485,972 shares traded.

Analyst Ratings Changes

Several equities research analysts have weighed in on ABUS shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Thursday, June 6th. Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, June 5th. JMP Securities raised their price objective on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday, August 2nd. Finally, StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th.

Arbutus Biopharma Trading Up 1.0 %

The business’s fifty day moving average is $3.60 and its 200 day moving average is $3.15.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Arbutus Biopharma had a negative return on equity of 66.68% and a negative net margin of 766.20%. The company had revenue of $1.73 million for the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the previous year, the business earned ($0.10) earnings per share. Analysts predict that Arbutus Biopharma Co. will post -0.38 EPS for the current year.

Institutional Investors Weigh In On Arbutus Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABUS. BNP Paribas Financial Markets increased its stake in Arbutus Biopharma by 20.5% in the 4th quarter. BNP Paribas Financial Markets now owns 292,045 shares of the biopharmaceutical company’s stock valued at $730,000 after buying an additional 49,745 shares during the last quarter. Cowen AND Company LLC bought a new position in shares of Arbutus Biopharma in the 4th quarter valued at about $125,000. Premier Path Wealth Partners LLC grew its position in shares of Arbutus Biopharma by 37.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 30,500 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 8,300 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Arbutus Biopharma by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 32,233 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 12,833 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Arbutus Biopharma in the 1st quarter valued at about $266,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.